source
- AstraZeneca’s Etcamah fails Phase 3 trial, dashing hopes for $2.9 billion breast cancer marketAstraZeneca’s oral selective estrogen receptor degrader Etcamah was evaluated in the Phase 3 SERENA-4 trial as a first-line option for patients with ER-positive, HER2-negative advanced breast cance…
- FDA approves Moderna’s mRNA flu vaccine as company reports positive Phase 3 cancer vaccine resultsThe FDA has granted approval to Moderna’s mRNA‑based flu vaccine, marking a notable rebound for the technology after the Trump administration cut $500 million in funding for mRNA programs a year ea…BioSpace · 9h agoApprovalPositive